Enzyme-Instructed Self-Assembly of Small D-Peptides as a Multiple-Step Process for Selectively Killing Cancer Cells

Jie Zhou1, Xuewen Du1, Natsuko Yamagata1

  • 1Department of Chemistry, Brandeis University , 415 South Street, Waltham, Massachusetts 02453, United States.

Insights

Scientists developed enzyme-instructed self-assembly (EISA) using D-tetrapeptides to selectively kill cancer cells overexpressing alkaline phosphatases (ALPs). This biomimetic approach offers a new strategy for targeted cancer therapy.

Area of Science:

  • Biomaterials Science
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Selective cancer cell inhibition is a persistent challenge in chemotherapy.
  • Enzyme-instructed self-assembly (EISA) offers a potential strategy for targeted drug delivery and cancer therapy.

Purpose of the Study:

  • To validate enzyme-instructed self-assembly (EISA) as a multi-step process for selectively killing cancer cells overexpressing alkaline phosphatases (ALPs).
  • To design and synthesize novel D-tetrapeptides for EISA-based cancer therapy.

Main Methods:

  • Synthesis of D-tetrapeptides with phosphotyrosine residues and naphthyl capping.
  • Enzymatic dephosphorylation by alkaline phosphatases (ALPs).
  • Assessment of self-assembly into nanofibers and cellular inhibition assays using cancer and normal cell lines.

Main Results:

  • Dephosphorylation of D-tetrapeptides triggers self-assembly into nanofibers.
  • Mono- and diphosphorylated D-tetrapeptides selectively inhibit cancer cells overexpressing ALPs, while remaining innocuous to normal cells.
  • Inhibitory activity correlates with ALP levels and self-assembly efficiency; cell death mechanisms involve death receptors.

Conclusions:

  • EISA is a viable strategy for selective cancer cell killing, leveraging ALP overexpression.
  • The D-tetrapeptide nanofibers demonstrate potent anticancer activity through targeted self-assembly and interaction with cancer cells.
  • This biomimetic approach provides molecular insights for developing supramolecular assemblies as anticancer therapeutics.